A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists

Journal of Applied Genetics

Volumn 50, Issue 4, 2009, Pages 399-403

  Stepien E ^a,b   Branicka, A ^a   Ciesla Dul M ^a   Undas, A ^b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antivitamin K; Coumarin resistance; Human; Pharmacogenetics; Polymorphism; Thromboembolism

Indexed keywords

EID: 70350675161     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03195700     Document Type: Article

References (19)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, 2008. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S.
2. Blann A, Bareford D, 2004. Ethnic background is a determinant of average warfarin dose required to maintain the INR between 3.0 and 4.5. J Thromb Haemost 2: 525-526.
3. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. 2005. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotype as determinants of acenocoumarol sensitivity. Blood 106: 135-140.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649.
5. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. 1993. Risk factors for complications of chronic anticoagulation. Ann Intern Med 118: 511-520.
6. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. 2005. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemostasis 94: 773-779.
7. Hackam DG, Kopp A, Redelmeier DA, 2005. Prognostic implications of warfarin cessation after major trauma: a population-based cohort analysis. Circulation 111:2 250-2256.
8. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, et al. 2008. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemostasis 6: 1663-1670.
9. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, et al. 2006. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43: 740-744.
10. Martini, Ligia Araújo, 2007. Relationship between diet and anticoagulant response to warfarin: a factor analysis. Eur J Nutr 46: 147-154.
11. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH, 2007. Factors influencing warfarin dose requirements in African-Americans Pharmacogenomics 8: 1535-1544.
12. Osman A, Enström C, Arbring K, Söderkvist P, Lindahl TL, 2006. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemostasis 4: 1723-1729.
13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engel J Med 352: 2285-2293.
14. Salobir B, Sabovic M, Peternel P, 2002. Intensity of long-term treatment with warfarin is influenced by seasonal variations. Pathophysiol Haemost Thromb 32: 151-154.
15. Sawicka-Powierza J, Rogowska-Szadkowska D, Ołtarzewska A.M, Chlabicz S, 2008. Factors influencing activity of oral anticoagulants. Interactions with drugs and food. Pol Merk Lek 143: 458-462.
16. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333.
17. Thacker SM, Grice GR, Milligan PE, Gage BF. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. 2008. J Thromb Haemost 6: 1445-1449.
18. van Leeuwen Y, Rosendaal FR, van der Meer FJ, 2008. The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res 123: 225-230.
19. Wilms EB, Touw DJ, Conemans JM, Veldkamp R, Hermans M, 2008. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemostasis 6: 1224-1226.